Cystic Fibrosis
Conditions
Brief summary
Safety and tolerability assessments as determined by adverse events (AEs), clinical laboratory values, standard 12-lead ECGs, vital signs, and pulse oximetry
Detailed description
Absolute change in sweat chloride (SwCl)
Interventions
DRUGVX-770 75mg
DRUGVX-770 granules
DRUGKaftrio 75 mg/50 mg/100 mg granules in sachet
DRUGKaftrio 60 mg/40 mg/80 mg granules in sachet
DRUGVX-770 50mg
DRUGIvacaftor 25 mg granules
Sponsors
Vertex Pharmaceuticals Inc.
Eligibility
Sex/Gender
All
Age
0 Years to 17 Years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety and tolerability assessments as determined by adverse events (AEs), clinical laboratory values, standard 12-lead ECGs, vital signs, and pulse oximetry | — |
Secondary
| Measure | Time frame |
|---|---|
| Absolute change in sweat chloride (SwCl) | — |
Countries
Denmark, Germany, Netherlands
Outcome results
None listed